Novartis Just Paid $2 Billion for a Drug That Doesn't Have Data Yet

Everyone Wants a Piece of This Market

Novartis isn't the only pharma company that noticed Piqray's limitations and decided to build a better mousetrap. The race for next-generation PI3Kα inhibitors has turned into one of the most competitive corridors in oncology.

Eli Lilly paid up to $2.5 billion in January 2025 for Scorpion Therapeutics and its drug STX-478, which is in Phase 1/2 trials for the same patient population. AstraZeneca has Truqap, approved in 2023, which pulled in $684 million in sales last year. And Roche launched Itovebi in late 2024, though its sales have been more modest.

This is what makes the Novartis deal so fascinating. The front-loaded deal structure (two-thirds of the potential $3 billion total is upfront cash) screams urgency.

Why Novartis Couldn't Afford to Wait

The strategic math here goes beyond one drug. Kisqali (ribociclib), Novartis's blockbuster CDK4/6 inhibitor for breast cancer, is a franchise-defining drug. And SNV4818 is designed specifically to pair with it.

If SNV4818 works as hoped, Novartis could offer oncologists a powerful combination: Kisqali to block one cancer growth pathway, SNV4818 to block another, and endocrine therapy to cut off hormone fuel. A three-pronged attack on the most common form of breast cancer, all from the same company.

There's also the defensive angle. Piqray is getting outflanked. Truqap and Itovebi are both newer, both approved, and both eating into its market share. Novartis needed a next-generation asset to stay relevant in the PI3Kα space it helped create. Without SNV4818, it risked becoming the company that pioneered the category and then watched competitors take it over.

Meanwhile, Novartis is staring down patent expirations on its cardiovascular blockbuster Entresto. The company needs new growth engines, and oncology is where it's placing its chips. This deal follows the $12 billion acquisition of Avidity Biosciences, signaling that Novartis is in full shopping mode.

The $2 Billion Question

Is this deal brilliant or reckless? The honest answer: we won't know for at least a year.

The bull case is compelling. Mutant-selective PI3Kα inhibition is the clear direction the field is moving. SNV4818 could become the backbone of Novartis's breast cancer franchise for the next decade, especially in combination with Kisqali. The addressable market (40% of HR+/HER2- patients) is enormous.

The bear case is equally real. Phase 1/2 assets fail all the time. We have no efficacy data yet. If SNV4818 stumbles in trials, that $2 billion upfront payment becomes one of the most expensive mistakes in recent pharma history.

Analysts at Zacks noted the deal's alignment with "premium pricing potential in a biomarker-defined market." Investors, for now, seem willing to give the company the benefit of the doubt.

But the clock is ticking. Novartis needs SNV4818 to move fast through clinical development. In the race for next-generation breast cancer drugs, being second to market with a slightly better drug is a perfectly viable strategy. Being third or fourth is not.

The deal is expected to close in the first half of 2026. After that, all eyes turn to those 2027 trial readouts. Novartis just wrote a very large check. Now it has to wait and see if the science cashes it.